J

Johnson & Johnson

Makes prescription drugs and medical devices

R&D Lead Site Contract Manager - Multiple Teams

Full-Time
No salary listed
Mid, Senior
Bachelor's
Chiyoda City, Tokyo, Japan
HybridHybrid work in Chiyoda, Tokyo; travel is 10%.
Contract Management

About the job

Requirements
  • A bachelor's degree in an appropriate scientific or business discipline.
  • Three to five years of experience and/or equivalent competencies in the pharmaceutical industry or clinical research.
  • Working knowledge of the clinical development process and two years of negotiation and contract experience.
  • Excellent oral and written communication skills.
  • Familiarity with healthcare compliance and relevant guidance, including HIPAA, FCPA, and Safe Harbor, and comprehensive knowledge of clinical research processes.
  • Ability to work effectively in cross-functional teams.
  • Strong initiative and ability to work independently as a self-starter.
  • Strong negotiation and problem-resolution skills.
  • Working knowledge of PCs, including the Microsoft Office suite, and database management.
  • Strong interpersonal skills and ability to accomplish substantial tasks with minimal supervision.
  • Adherence to standard operating procedures, ethics, and departmental compliance requirements, including applicable corporate, operating company, Healthcare Compliance, and Quality Assurance guidelines.
  • Familiarity with departmental and corporate processes, including processes associated with CCS GD and operating companies.
  • Compliance with requests from Quality Assurance and auditors.
  • Ability to work independently and collaboratively in a team environment.
  • Fluency in English.
  • Ability to travel 10%.
Responsibilities
  • Prepare, negotiate, and finalize clinical trial agreements and ancillary agreements for company-sponsored and/or investigator-initiated studies through direct negotiation with clinical trial sites or oversight of a Clinical Research Organization responsible for contract negotiations.
  • Analyze requirements and translate them into appropriate contracts and budgets for clinical trial agreements and other relevant legal documents.
  • Review study-specific tracking requirements for accuracy and completeness and deliver against contracting cycle-time targets.
  • Work with global teams to review and analyze contractual terms and conditions.
  • Assess legal and budget risks with team support functions; partner with Healthcare Compliance, Risk Management, Privacy, and other stakeholders to obtain guidance and resolve issues.
  • Analyze investigator fees against fair-market-value pricing and ensure alignment with regional standards and J&J pricing guidelines.
  • Participate in and/or lead approval escalations as appropriate.
  • Provide specialized support and guidance for negotiations involving confidentiality agreements, informed consent forms, and other ancillary contract documents.
  • Determine potential needs for contract amendments and manage the amendment lifecycle.
  • Ensure contractual terms and provisions comply with corporate processes, systems, and strategies.
  • Provide project-management oversight to CROs contracted to negotiate CTAs globally, including training and supervision to ensure adherence to timelines and targets.
  • Onboard and train new staff, meet regularly with team members to ensure studies are properly supported, identify contracting issues and potential solutions, and assist in resolving site- and study-related concerns.
  • Mentor and guide teams on processes and procedures; serve as a key liaison with management on staff performance and development; and facilitate clear, consistent communications between management and team members.
  • Identify and implement process improvements and drive accountability and results.
  • Assist in the review, authorization, and/or management of payments.
  • Assist clinical operations or the clinical team in ensuring investigator grants comply with overall study costs and compliance guidelines.
Desired Qualifications
  • Previous experience working in virtual teams.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
The Irish Times
Oct 28th, 2026
Johnson & Johnson buys Irish stroke care firm in multimillion euro deal

Sale of Neuravi is largest deal for a venture-backed medtech in Europe since 2009

Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.